Has Aasim Sehbai, MD received payments from drug or device companies?

Yes. Drug and device makers reported $176,999 in general payments to Aasim Sehbai, MD across 1,140 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aasim Sehbai, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aasim Sehbai, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aasim Sehbai, MD

Hematology & Oncology · Anniston, ALNPI 1689629602

Payments from drug & device makers

$176,999in general payments, 2019–2025

Across 1,140 payments — averaging $155.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka Pharmaceutical Co., Ltd.$136K
E.r. Squibb & Sons, L.L.C.$12K
Novartis$8K
AstraZeneca$5K
GSK$2K
Johnson & Johnson$1K
plus $13K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka Pharmaceutical Co., Ltd.	22	$135,888
E.r. Squibb & Sons, L.L.C.	102	$12,171
Novartis	214	$7,599
AstraZeneca(2 entities)	60	$4,683
GSK	19	$2,291
Johnson & Johnson	66	$1,346
Seagen Inc.	48	$1,025
Pfizer	84	$1,007
Amgen	52	$975
Merck	52	$907
Lilly USA, LLC	43	$661
Bristol Myers Squibb	26	$600
Galt Pharmaceuticals, LLC	1	$562
Sobi, Inc	20	$487
AbbVie	23	$439
Takeda Pharmaceuticals U.S.A., Inc.	19	$431
Sanofi	17	$417
Jazz Pharmaceuticals Inc.	14	$319
Gilead(2 entities)	18	$319
Stemline Therapeutics Inc.	11	$303
Regeneron Healthcare Solutions, Inc.	15	$256
Eisai Inc.	14	$254
Boehringer Ingelheim	11	$233
Daiichi Sankyo Inc.	10	$193
Pharmaessentia USA Corporation	8	$189
Octapharma USA, Inc.	7	$183
Array Biopharma Inc	8	$182
Athenex Pharmaceutical Division, LLC	1	$175
Astellas Pharma US Inc	9	$174
Global Blood Therapeutics, Inc.	10	$174
Puma Biotechnology, Inc.	8	$168
Karyopharm Therapeutics Inc.	10	$163
Dova Pharmaceuticals	6	$132
ADC Therapeutics America, Inc.	3	$130
Genentech USA, Inc.	7	$129
Blueprint Medicines Corporation	6	$126
Beone Medicines USA, Inc.	7	$122
Incyte Corporation	6	$121
Bayer	5	$106
Progenics Pharmaceuticals, Inc.	6	$105
Servier Pharmaceuticals LLC	5	$90
EMD Serono, Inc.	4	$82
Pharmacyclics LLC, An Abbvie Company	5	$79
Beigene USA, Inc.	4	$72
Tempus AI, Inc	3	$69
AVEO Pharmaceuticals, Inc.	3	$67
Sumitomo Pharma America, Inc.	4	$65
Genmab U.S., Inc.	3	$59
Rigel Pharmaceuticals, Inc.	5	$53
Coherus Oncology, Inc.	3	$53
Atland Pharmaceuticals, LLC	1	$49
Myriad Genetic Laboratories, Inc.	3	$45
Spectrum Pharmaceuticals Inc.	3	$43
Myovant Sciences Inc.	3	$42
Partner Therapeutics, Inc.	2	$42
Dendreon Pharmaceuticals LLC	1	$29
Immunomedics, Inc.	1	$24
Novocure Inc.	1	$24
Agios Pharmaceuticals, Inc.	1	$21
Springworks Therapeutics, Inc.	1	$19

How this compares

$176,999 in reported general payments places this provider in the 70th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$1,897,711

Medicare patients

397

Services billed

129,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Anniston

Luciano CostaBirmingham$32.8M
Amitkumar MehtaBirmingham$18.6M
Erica Stringer-ReasorBirmingham$18.1M
Susan BalBirmingham$11.3M
Pankit VachhaniBirmingham$7.9M
Mehmet AkceBirmingham$5.4M
Michael MeshadMobile$5.3M
Mayur NarkhedeBirmingham$4.9M
Christos VaklavasBirmingham$4.9M
Lisle NabellBirmingham$3.3M

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →